Literature DB >> 11012760

Structure/function studies of human decay-accelerating factor.

W G Brodbeck1, L Kuttner-Kondo, C Mold, M E Medof.   

Abstract

The decay-accelerating factor (DAF) contains four complement control protein repeats (CCPs) with a single N-linked glycan positioned between CCPs 1 and 2. In previous studies we found that the classical pathway regulatory activity of DAF resides in CCPs 2 and 3 while its alternative pathway regulatory activity resides in CCPs 2, 3 and 4. Molecular modelling of the protein predicted that a positively charged surface area on CCPs 2 and 3 (including KKK125-127) and nearby exposed hydrophobic residues (L147F148) on CCP3 may function as ligand-binding sites. To assess the roles of the N-linked glycan and the above two sets of amino acids in the function of DAF, we mutated N61 to Q, KKK125-127 to TTT and L147F148 to SS. Following expression of the mutated cDNAs in Chinese hamster ovary cells, the glycosylphosphatidylinositol (GPI)-anchored mutant proteins were affinity purified and their functions were assessed. In initial assays, the proteins were incorporated into sheep and rabbit erythrocytes and the effects of the mutations on regulation of classical and alternative C3 convertase activity were quantified by measuring C3b deposition. Since DAF also functions on C5 convertases, comparative haemolytic assays of cells bearing each mutant protein were performed. Finally, to establish if spatial orientation between DAF and the convertases on the cell surface played any role in the observed effects, fluid-phase C3a generation assays were performed. All three assays gave equivalent results and showed that the N-linked glycan of DAF is not involved in its regulatory function; that L147F148 in a hydrophobic area of CCP3 is essential in both classical and alternative pathway C3 convertase regulation; and that KKK125-127 in the positively charged pocket between CCPs 2 and 3 is necessary for the regulatory activity of DAF on the alternative pathway C3 convertase but plays a lesser role in its activity on the classical pathway enzyme.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012760      PMCID: PMC2327052          DOI: 10.1046/j.1365-2567.2000.00086.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.

Authors:  H A Stafford; M L Tykocinski; D M Lublin; V M Holers; W F Rosse; J P Atkinson; M E Medof
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases.

Authors:  M Krych-Goldberg; R E Hauhart; V B Subramanian; B M Yurcisin; D L Crimmins; D E Hourcade; J P Atkinson
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

3.  A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement.

Authors:  M K Pangburn
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

4.  Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55).

Authors:  S J Hinchliffe; O B Spiller; N K Rushmere; B P Morgan
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

5.  Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).

Authors:  T Seya; V M Holers; J P Atkinson
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

6.  Sites within the complement C3b/C4b receptor important for the specificity of ligand binding.

Authors:  M Krych; D Hourcade; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

7.  Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins.

Authors:  I W Caras; M A Davitz; L Rhee; G Weddell; D W Martin; V Nussenzweig
Journal:  Nature       Date:  1987 Feb 5-11       Impact factor: 49.962

8.  Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.

Authors:  M E Medof; D M Lublin; V M Holers; D J Ayers; R R Getty; J F Leykam; J P Atkinson; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

9.  Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.

Authors:  M E Medof; E I Walter; W L Roberts; R Haas; T L Rosenberry
Journal:  Biochemistry       Date:  1986-11-04       Impact factor: 3.162

Review 10.  Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.

Authors:  T Kinoshita; M E Medof; R Silber; V Nussenzweig
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  16 in total

1.  Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.

Authors:  O Brad Spiller; Mairi Robinson; Elizabeth O'Donnell; Steven Milligan; B Paul Morgan; Andrew J Davison; David J Blackbourn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Complement regulation at the molecular level: the structure of decay-accelerating factor.

Authors:  P Lukacik; P Roversi; J White; D Esser; G P Smith; J Billington; P A Williams; P M Rudd; M R Wormald; D J Harvey; M D M Crispin; C M Radcliffe; R A Dwek; D J Evans; B P Morgan; R A G Smith; S M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

3.  Solution structure of a functionally active fragment of decay-accelerating factor.

Authors:  Stanislava Uhrinova; Feng Lin; Graeme Ball; Krystyna Bromek; Dusan Uhrin; M Edward Medof; Paul N Barlow
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

4.  Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

Authors:  Geoffrey Gifford; Vivian P Vu; Nirmal K Banda; V Michael Holers; Guankui Wang; Ernest V Groman; Donald Backos; Robert Scheinman; S Moein Moghimi; Dmitri Simberg
Journal:  J Control Release       Date:  2019-04-08       Impact factor: 9.776

5.  Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.

Authors:  F Lin; Y Fukuoka; A Spicer; R Ohta; N Okada; C L Harris; S N Emancipator; M E Medof
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 6.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  Each GPI-anchored protein species forms a specific lipid raft depending on its GPI attachment signal.

Authors:  Arisa Miyagawa-Yamaguchi; Norihiro Kotani; Koichi Honke
Journal:  Glycoconj J       Date:  2015-05-07       Impact factor: 2.916

8.  Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.

Authors:  Jennifer White; Petra Lukacik; Dirk Esser; Michael Steward; Naomi Giddings; Jeremy R Bright; Sarah J Fritchley; B Paul Morgan; Susan M Lea; Geoffrey P Smith; Richard A G Smith
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

9.  Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55.

Authors:  Sylvie Hudault; O Brad Spiller; B Paul Morgan; Alain L Servin
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.

Authors:  J M Heckmann; H Uwimpuhwe; R Ballo; M Kaur; V B Bajic; S Prince
Journal:  Genes Immun       Date:  2009-08-13       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.